Ontario To Spend $20 Billion On Four Small Nuclear Reactors
The Province of Ontario plans to spend $20.9 billion ($15.1 billion U.S.) to build a total of four small modular nuclear reactors. Ontario Power Generation has inked a deal with GE Vernova (GEV) to build four of the nuclear reactors in the province. The first reactor will be located at the power company’s Darlington Nuclear Project site in Clarington, Ontario.The initial unit is expected to cost $6.1 billion, and future costs for the additional three nuclear reactors are expected to decline as GE Vernova gains expertise in building them.While still a nascent industry, interest in nuclear power is rising around the world as technology companies and governments look to clean power to meet future electricity demand.The technology industry, in particular, is considering small modular nuclear reactors to help power their artificial intelligence (A.I.) data centres. In signing the agreement with GE Vernova, Canada became the first Group of Seven (G7) nation to move forward with the development of small modular nuclear reactors. The small modular reactors, or SMRs as they are known. are expected to be produced in factories and then assembled onsite, a strategy that is expected to keep costs down. The Government of Ontario says it is moving forward with the nuclear reactors because, by 2050, its power needs are forecast to rise 75%. The stock of GE Vernova has risen 137% over the past year as surging demand for power, driven by data centres and new factories, has driven its financial results higher. GE Vernova shares currently trade at $394 U.S. each.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


